Browsing by Author "Gumedze, Freedom N"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- ItemOpen AccessAnalysis of clustered competing risks with application to a multicentre clinical trial(2016) Familusi, Mary Ajibola; Gumedze, Freedom NThe usefulness of time-to-event (survival) analysis has made it gain a wide applicability in statistically modelling research. The methodological developments of time-to-event analysis that have been widely adopted are: (i) The Kaplan-Meier method, for estimating the survival function; (ii) The log-rank test, for comparing the equality of two or more survival distributions; (m) The Cox proportional hazards model, for examining the covariate effects on the hazard function; and (iv) The accelerated failure time model, for examining the covariate effects on the survival function. Nonetheless, in time-to-event endpoints assessment, if subjects can fail from multiple mutually-exclusive causes, data are said to have competing risks. For competing risks data, the Fine and Gray proportional hazards model for sub-distributions has gained popularity due to its convenience in directly assessing the effect of covariates on the cumulative incidence function. Furthermore, sometimes competing risks data cannot be considered as independent because of a clustered design; for instance, in registry cohorts or multi-centre clinical trials. The Fine and Gray model has been extended to the analysis of clustered time-to-event data, by including random-centre effects or frailties in the sub-distribution hazard. This research focuses on the analysis of clustered competing risks with an application to the investigation of the management of pericarditis clinical trial (IMPI) dataset. IMPI is a multi- centre clinical trial that was carried out from 19 centres in 8 African countries with the principal objective of assessing the effectiveness and safety of adjunctive prednisolone and Mycobacterium indicus pranii immunotherapy, in reducing the composite outcome of death, constriction or cardiac tamponade, requiring pericardial drainage in patients with probable or definite tuberculous pericarditis. The clinical objective in this thesis is therefore to analyse time to these outcomes. In addition, the risk factors associated with these outcomes were determined, and the effect of the prednisolone and M. indcus pranii was examined, while adjusting for these risk factors and considering centres as a random effect. Using Cox proportional hazards model, it was found that age, weight, New York Heart Association (NYHA) class, hypotension, creatinine, and peripheral oedema show a statistically significant association with the composite outcome. Furthermore, weight, NYHA class, hypotension, creatinine and peripherial oedema show a statistically significant association with death. In addition, NYHA class and hypotension show a statistically significant association with cardiac tamponade. Lastly, prednisolone, gender, NYHA class, tachycardia, haemoglobin level, peripheral oedema, pulmonary infiltrate and HIV status show a statistically significant association with constriction. A value of 0.1 significance level was used to identify variables as significant in the univariate model using forward stepwise regression method. The random effect was found to be significant in the incidence of composite outcomes of death, cardiac tamponade and constriction, and in the individual outcome of constriction, but this only slightly changed the estimated effect of the covariates as compared to when the random effect was not considered. Accounting for death as a competing event to the outcomes of cardiac tamponade or constriction, does not affect the effect of the covariates on these outcomes. In addition, in the multivariate models that adjust for other risk factors, there was no significant difference in the primary outcome between patients who received prednisolone, and those who received placebo, or between those who received M. indicus pranii immunotherapy, and those who received placebo.
- ItemOpen AccessModelling relationships between clinical markers of the Human Immunodeficiency Virus disease in a South African population(1999) Gumedze, Freedom N; Juritz, JuneThis study investigated relationships between the CD4 count and other clinical markers of the HIV disease, total lymphocyte count and viral load, in a South African population. The CD4 count has been an important clinical marker of disease progression in HIV infected individuals,,-and has been the focus of many studies in developed countries. Most of the studies reported in the literature have been done using data from well-defined cohorts of HIV patients. Similar studies in Africa do not appear to have been done. This study used clinical records of HIV infected individuals attending the Somerset Hospital HIV Clinic, over the period 1984-97, to study the relationship between the CD4 count and total lymphocyte count. From a practical perspective this relationship is important in South Africa for two reasons. Firstly, a majority of the HIV infected population is poor and can not afford the higher costs associated with the measurement of the CD4 count instead of the total lymphocyte count. .. Secondly, in many small clinics or hospitals in South Africa the equipment for measuring the CD4 count is generally not available but the equipment for measuring the total lymphocyte count is widely available.
- ItemOpen AccessSensitivity analysis approaches for incomplete longitudinal data in a multi-centre clinical trial(2019) Iddrisu, Abdul-Karim; Gumedze, Freedom NThe first major contribution of the thesis is the development of sensitivity analysis strategy for dealing with incomplete longitudinal data. The second important contribution is setting up of simulation experiment to evaluate the performance of some of the sensitivity analysis approaches. The third contribution is that the thesis offers recommendations on which sensitivity analysis strategy to use and in what circumstance. It is recommended that when drawing statistical inferences in the presence of missing data, methods of analysis based on plausible scientific assumptions should be used. One major issue is that such assumptions cannot be verified using the data at hand. In order to verify these assumptions, sensitivity analysis should be performed to investigate the robustness of statistical inferences to plausible alternative assumptions about the missing data. The thesis implemented various sensitivity analysis strategies to incomplete longitudinal CD4 count data in order to investigate the effect of tuberculosis pericarditis (TBP) treatment on CD4 count changes over time. The thesis achieved the first contribution by formulating primary analysis (which assume that the data are missing at random) and then conducting sensitivity analyses to assess whether statistical inferences under the primary analysis model are sensitive to models that assume that the data are not missing at random. The second contribution was achieved via simulation experiment involving formulating hypotheses on how sensitivity analysis strategies would performed under varying rate of missing values and model mis-specification (when the model is mis-specified). The third contribution was achieved based on our experience from the development and application of the sensitivity analysis strategies as well as the simulation experiment. Using the CD4 count data, we observed that statistical inferences under the primary analysis formulation are robust to the sensitivity analyses formulations, suggesting that the mechanism that generated the missing CD4 count measurements is likely to be missing at random. The results also revealed that TBP does not interact with the HIV/AIDS treatment and that TBP treatment had no significant effect on CD4 count changes over time. We have observed in our simulation results that the sensitivity analysis strategies produced unbiased statistical inferences except when a strategy is inappropriately applied in a given trial setting and also, when a strategy is mis-specified. Although the methods considered were applied to data in the IMPI trial setting, these methods can also be applied to clinical trials with similar settings. A sensitivity analysis strategy may not necessarily give bias results because it has been mis-specified, but it may also be that it has been applied in a wrongly defined trial setting. We therefore strongly encourage analysts to carefully study these sensitivity analysis frameworks together with a clearly and precise definition of the trial objective in order to decide on which sensitivity analysis strategy to use.